Last updated: February 16, 2026
What Is the Market Status of NDC 25021-0174?
NDC 25021-0174 is a prescription medication marketed under the Tamiflu brand, which contains oseltamivir phosphate. Approved by the FDA, Tamiflu is used for the treatment and prevention of influenza. It is a well-established antiviral with a significant global market share during flu seasons.
How Large Is the Market for Oseltamivir (NDC 25021-0174)?
Global Market Size
The antiviral influenza market experienced growth driven by seasonal demand, pandemic preparedness, and increasing awareness. The global market value was approximately USD 1.2 billion in 2022, with projections reaching USD 1.4 billion by 2028, representing a compound annual growth rate (CAGR) of roughly 3.1% [1].
U.S. Market Breakdown
In the United States, Tamiflu accounts for an estimated 60% of the prescription influenza antiviral market. The U.S. influenza antiviral market was valued at roughly USD 350 million in 2022, with annual sales fluctuating based on flu activity levels. The market responds to seasonal demand but remains stable due to the drug's long-standing approval and inclusion in national stockpiles [2].
Prescription Trends
- Peak prescriptions: During flu seasons, Tamiflu prescriptions can spike by 200-300% compared to off-season months.
- Reimbursement: Medicare and private insurers broadly cover Tamiflu, facilitating market stability.
Competitive Landscape
Tamiflu competes with other antivirals such as zanamivir (Relenza), baloxavir marboxil (Xofluza), and emerging generics. The entry of generics has begun to pressure branded prices since patent expiration in 2016.
What Are the Pricing Trends for NDC 25021-0174?
Branded Price Dynamics
- Average wholesale price (AWP): Historically, Tamiflu's AWP ranged from USD 140 to USD 180 per treatment course.
- Retail price: Insurance typically reimburses most of this, with patient copayments averaging USD 20-50 per course.
Generic Entry Impact
Since patent expiry, generic oseltamivir has entered the market, leading to price erosion:
| Year |
Estimated Price per Treatment Course |
Source |
| 2017 |
USD 70 |
[3] |
| 2020 |
USD 50 |
[4] |
| 2022 |
USD 35 |
Market reports |
Price reductions stem from increased competition and manufacturing efficiencies among generic producers.
Future Price Projections
- Short-term (1-2 years): Prices are expected to stabilize around USD 30-40 per course due to market penetration of generics.
- Mid-term (3-5 years): Further price declines are unlikely barring new formulations or regulatory changes, with estimates around USD 25-30.
What Factors Influences Future Market and Pricing?
- Pandemic Preparedness: Stockpiling policies and pandemic response measures bolster demand occasionally.
- Regulatory Approvals: New formulations, pediatric indications, or combination therapies could modify market access and pricing.
- Generics Market: Continued competition among generics pushes prices downward.
- Seasonal Variations: Flu seasons will drive temporary spikes in demand.
How Do Market Conditions Compare to Similar Antivirals?
- Baloxavir (Xofluza): Approved in 2018, priced around USD 150 for a single-dose regimen. Its market share is limited but growing, particularly among high-risk populations.
- Zanamivir (Relenza): Inhaled, priced higher with limited prescription volume, representing a niche segment.
Key Takeaways
- Market size remains stable with seasonal peaks; the global market is forecasted to grow modestly.
- Brand prices have decreased significantly following patent expiration; generic competition dominates.
- Pricing is likely to stabilize around USD 25-40 per treatment course over the next few years.
- Public health policies and pandemic preparedness efforts have a direct impact on demand fluctuations.
- Competitive pressures from newer antivirals, such as baloxavir, influence market share and pricing strategies.
FAQs
1. What is the current patent status of NDC 25021-0174?
The original patent expired in 2016, allowing generics to enter the market and reduce prices.
2. How does the emergence of generics affect market prices?
Generics drive prices downward by increasing competition, often reducing the treatment course cost by up to 50% or more.
3. Are there new formulations or indications in development for oseltamivir?
As of 2023, no new formulations are pending approval; ongoing research focuses on combination therapies and pediatric formulations.
4. How does influenza vaccine coverage influence the antiviral market?
Higher vaccination rates reduce overall demand for antivirals. However, during outbreaks or vaccine mismatches, antiviral demand spikes.
5. What is the impact of COVID-19 on the influenza antiviral market?
Pandemic response measures and social distancing decreased influenza cases temporarily, reducing antiviral prescriptions in 2020 and 2021, but market expectations for recovery exist.
References
[1] Markets and Markets, "Antiviral Drugs Market," 2022.
[2] IQVIA, Prescription Data, 2022.
[3] Walgreens, Domestic Market Data, 2017.
[4] Drug Price Competition and Patent Term Restoration Act Reports, 2020.
